Clinical trial · Interventional
Phase I Study in Patients With Solid Tumours
A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours
NCT00496028CI-TRIAL-00003950completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD0530 | Drug | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1
- description
- AZD0530 + Paclitaxel
- interventionNames
- Drug: AZD0530
- Drug: Paclitaxel
- type
- EXPERIMENTAL
- label
- 2
- description
- AZD0530 + Carboplatin
- interventionNames
- Drug: AZD0530
- Drug: Carboplatin
- type
- EXPERIMENTAL
- label
- 3
- description
- AZD0530 + Carboplatin + Paclitaxel
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Life expectancy \> 12 weeks * Women defined as post-menopausal * Male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel Exclusion Criteria: * Inadequate bone marrow reserve * Inadequate live function, renal function or low haemoglobin * Unresolved toxicity from anti-cancer therapy
References
Publications (0)
Data not yet available
No reference posted for this study.